Clinical Trials Logo

Malignancy clinical trials

View clinical trials related to Malignancy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05803096 Completed - Prostate Cancer Clinical Trials

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Start date: December 12, 2021
Phase: Phase 4
Study type: Interventional

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

NCT ID: NCT04936997 Completed - Cancer Clinical Trials

Immune Response to the COVID-19 Vaccine

Start date: June 7, 2021
Phase: Early Phase 1
Study type: Interventional

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

NCT ID: NCT04495530 Completed - Cancer Clinical Trials

Information Needs Around Parenteral nUTrition in Cancer

INPUT
Start date: January 19, 2021
Phase:
Study type: Observational

This study will explore the information needs of patient's with advanced cancer, and their carers, when making a decision to commence or discontinue parenteral nutrition. Interviews will be conducted with both patients with advanced cancer, and their carers to determine the information they need to make a shared decision with the healthcare team.

NCT ID: NCT04341974 Completed - Surgery Clinical Trials

Perioperative Use of Serum Creatinine and Postoperative Acute Kidney Injury

CreaPeriop
Start date: January 1, 2019
Phase:
Study type: Observational

The perioperative approach adopted in a cohort of adult oncological patients undergoing major abdominal surgery will be described. In particular, the physician's attitude toward use of sCr for identification of patients at risk for PO-AKI will be described, as well as the patients who should be reassessed in the long term for progression toward CKD. The incidence and risk factors associated with PO-AKI and renal function deterioration within a year postoperatively will be also evaluated.

NCT ID: NCT04257240 Completed - Liver Cancer Clinical Trials

Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

annie-liver
Start date: January 1, 2000
Phase:
Study type: Observational

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

NCT ID: NCT03961217 Completed - Prostate Cancer Clinical Trials

Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes

Start date: January 1991
Phase:
Study type: Observational [Patient Registry]

The investigators plan to investigate the consequences of late effects (radiation-induced survivorship syndromes) after radiotherapy in Gynecological and Prostate cancer survivors on return to work (Yes/No) and if RTW happened then time to RTW. In addition, whether general health, type of work (occupation), work environment factors, individual factors (lifestyle, socioeconomic status etc.), contribute to the adverse late effects of radiotherapy and these Gynecological cancer survivors have a higher risk for disability pension/long term sickness absence (NOT Return to work).

NCT ID: NCT03909464 Completed - Cancer Clinical Trials

Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy

Start date: November 29, 2017
Phase:
Study type: Observational

Problem: A significant proportion of patients with cancer experience symptoms of sensory, motor or autonomic nerve damage from chemotherapy known as chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a major dose-limiting toxicity of many chemotherapeutic regimens. Little is known about the natural history of CIPN, and the early detection and quantification of CIPN is a significant challenge. Design: The investigators propose a cohort study to evaluate the performance of the Pressure-Specified Sensory Device TM (PSSD) in assessing CIPN associated with various common chemotherapy regimens. The proposed study will examine peripheral nerve function before, during, and after chemotherapy treatment. Peripheral neuropathy will be assessed using the PSSD, the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) CIPN-20, and the Michigan Neuropathy Screening Instrument (MNSI). These are all established and validated methods to screen for a variety of conditions that cause peripheral neuropathy. Hypotheses: The investigators hypothesize that the PSSD will be a sensitive and specific tool for measuring CIPN. The onset of CIPN as detected by the PSSD will be compared with other screening modalities including the EORTC QLQ-CIPN20 and the MNSI. Importance: The development of CIPN often goes unnoticed until symptoms are bothersome. Having an objective tool in the care team's armament to screen for CIPN could have a significant public health impact.

NCT ID: NCT03824366 Completed - Metastasis Clinical Trials

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

MAP-RT
Start date: April 23, 2019
Phase: N/A
Study type: Interventional

This proposed study is unique in that patients will not undergo computed tomography (CT) simulation at any point during their treatment course and will instead have same-session magnetic resonance (MR)-only simulation and treatment planning, on-table, using the adaptive radiotherapy (ART) workflow. In this manner, patients requiring urgent treatment could initiate treatment as early as the day of initial radiation oncology consultation.

NCT ID: NCT03688347 Completed - Cancer Clinical Trials

Microbiome in Lung Cancer and Other Malignancies

Start date: August 30, 2018
Phase:
Study type: Observational

To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.

NCT ID: NCT03415126 Completed - Cancer Clinical Trials

A Study of ASN007 in Patients With Advanced Solid Tumors

Start date: January 19, 2018
Phase: Phase 1
Study type: Interventional

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.